Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Brazil / NCT07295587
Enrolling by invitation Observational

Assessment of the Impact of Headache on the Employee Population of Libbs Pharmaceutical Ltd

NCT07295587 · tracked via the Priya Life Science Brazil tracker
Phase
Observational
Started
2026-01
Last updated
2025-12-19

Condition(s) studied

Migraine HeadacheMigraine

Study summary

The main objective of this study is to evaluate the impact of primary headaches using data previously collected in a healthcare program conducted by Libbs with its employees. The study aims to identify the main types of headaches, assess their impact on work and quality of life, describe treatment modalities and healthcare services used, and analyze possible correlations between job position or sector and the occurrence of headaches, as well as their impact on productivity.

This retrospective observational study analyzes secondary data collected from Libbs employees during a healthcare program designed to understand the impact of migraine on work productivity and daily activities. Data were obtained through validated questionnaires made available via an app. As this study involves the analysis of previously collected data, it does not provide direct benefits to participants. However, it contributes to a better understanding of migraine symptoms among Libbs employees, supports awareness of the risks of self-medication, and highlights the effects of headaches on daily routines and productivity.

No therapeutic intervention is proposed in this study. Decisions regarding diagnosis, interventions, and treatments were made exclusively by the Dr. Cefaleia app team at the time of data collection, without any interference related to the development of this research. The HIT-6 score and the four WPAI outcomes will be analyzed: absenteeism (lost work time), presenteeism (impairment while working), overall work productivity loss (absenteeism plus presenteeism), and impairment in activities outside of work.

This study provides an opportunity to expand the understanding of the relationship between working conditions, headaches, health, and productivity. The analysis may help identify epidemiological patterns and occupational or social risk factors associated with headaches, supporting future preventive strategies and workplace health initiatives aimed at improving quality of life and productivity.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * This analysis will include data from all employees who participated in this assistance program and made their data available in the Dr. Cefaleia app. Exclusion Criteria: * Data from participants whose questionnaires were not completed in full will be excluded.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Libbs Farmacêutica LTDA. São Paulo São Paulo

More Libbs Farmacêutica LTDA trials in Brazil

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07295587 on ClinicalTrials.gov ↗ ← All trials in Brazil